XORTX Therapeutics (XRX.CN) Buy, Sell or Hold

XORTX Therapeutics (XRX.CN)

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

0.00

-0.00 (0.00%)

17 watching

TOP PICK

Seen to have levelled out and has seen some moves recently. A small speculative company. Market cap is $74M. Continues to make new highs. A pharmaceutical company with 2 advanced products in trial. Enhancing safety to treat chronic kidney disease. Has some usage for covid patiences.

RISKY

Recently it's jumped from 10 to 17 cents/share. Reason: Covid attacks major organs (lungs, kidneys) and those with gout are particularly vulnerable; XRX has drugs to treat kidneys and uric acid (high levels lead to gout). XRX has two drugs going into phase-3 drug trials. He likes XRX a lot, but it's highly speculative though. XRX could out-license with one of three companies on a share-revenue basis.

Showing 1 to 2 of 2 entries

XORTX Therapeutics (XRX.CN) Frequently Asked Questions

What is XORTX Therapeutics stock symbol?

XORTX Therapeutics is a Canadian stock, trading under the symbol XRX.CN (previously XRX-CN on Stockchase) on the Canadian Securities Exchange (undefined). It is usually referred to as or XRX.CN

Is XORTX Therapeutics a buy or a sell?

In the last year, no analyst issued a Buy, Sell, or Hold rating on XRX.CN (previously XRX-CN on Stockchase) on Stockchase. Read the latest expert commentary for XORTX Therapeutics .

Is XORTX Therapeutics a good investment or a top pick?

XORTX Therapeutics was recommended as a Top Pick by Robert McWhirter on 2021-01-05. Read the latest stock experts ratings for XORTX Therapeutics .

Why is XORTX Therapeutics stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for XORTX Therapeutics .

Is XORTX Therapeutics worth watching?

XORTX Therapeutics is followed by 17 investors on Stockchase and is a trending stock that is worth watching.

Most Recent Experts

Jim Cramer - Mad Money

CNBC

Richard Orrell

RN Croft Financial Group

Stockchase Insights

5i Research

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Stan Wong

Private Wealth Management, ScotiaMcleod

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

XORTX Therapeutics (XRX.CN)